Mycotopia Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. 4 Top Stocks for Huge Gains from the Psychedelic Renaissance OTC Stock ReviewJanuary 25, 2021 GMT ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- OTC Stock Review was early to the party with an article on Seeking Alpha March 6, 2020 titled ” Psychedelic Medicine Stocks Capture the Attention of Investors.” Even though several of today’s market leaders were not public last March, since then several of the stocks covered in the article have made five and ten fold moves. Almost 11 months after that fir...

News Category Global Banking & Finance Reviews Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector MIAMI, Jan. 20, 2021 — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced today the Company has closed the transaction to sell 100% of its Mycotopia Therapy subsidiary to 20/20 Global Inc. (OTC Pink: TWGL). ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

[December 28, 2020] Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value MIAMI, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions, announced today the Company's Board of directors has elected to sell 100% of its Mycotopia Therapies subsidiary to 20/20 Global Inc. (OTC Pink: TWGL) for $350,000 while simultaneously acquiring approximately 75.77% of 20/20 Global’s outstanding...